Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
12-2013 | 12-2012 | 12-2011 | 12-2010 | 12-2009 | |
Assets | |||||
Current Assets | |||||
Cash & Cash Equivalents | 2,113,000 | 1,803,694 | 9,883,777 | 907,879 | 1,272,958 |
Marketable Securities | 19,000 | 58,556 | 16,491 | 1,190,789 | 384,017 |
Receivables | 2,182,000 | 1,751,388 | 1,951,167 | 1,621,966 | 1,389,534 |
Inventories | 1,697,000 | 1,744,982 | 1,389,983 | 1,203,809 | 1,051,771 |
Income taxes - deferred | 331,000 | 262,641 | 208,155 | 279,339 | 295,080 |
Other current assets | 91,000 | 84,302 | 5 | 116,244 | 66,891 |
TOTAL | $6,997,000 | $6,156,347 | $13,918,790 | $5,708,082 | $4,812,558 |
Non-Current Assets | |||||
PPE Net | 1,166,000 | 1,100,259 | 774,406 | 701,235 | 699,970 |
Investments And Advances | 439,000 | 719,836 | 63,704 | 3,219,403 | 2,247,871 |
Intangibles | 13,069,000 | 12,797,309 | 2,066,966 | 1,425,592 | 1,524,777 |
Other Non-Current Assets | 908,000 | 466,086 | 479,273 | 538,318 | 413,383 |
TOTAL | $15,582,000 | $15,083,490 | $3,384,349 | $5,884,548 | $4,886,001 |
Total Assets | $22,579,000 | $21,239,840 | $17,303,130 | $11,592,630 | $9,698,559 |
Liabilities | |||||
Current Liabilities | |||||
Short Term Debt | 2,697,000 | 1,169,490 | 1,572 | N/A | N/A |
Accounts payable and accrued liabilities | 1,256,000 | 1,327,339 | 1,206,052 | 803,025 | 810,544 |
Accrued Expenses | 1,261,000 | 949,741 | 720,789 | 472,650 | 381,141 |
TOTAL | $6,407,000 | $4,237,897 | $2,514,790 | $2,464,950 | $1,871,631 |
Non-Current Liabilities | |||||
Long Term Debt | 3,939,000 | 7,304,528 | 7,753,470 | 2,865,974 | 35,918 |
Deferred Revenues | 111,000 | 103,162 | 74,665 | 103,175 | 122,721 |
aiOther Non-Current Liabilities | 423,000 | 140,969 | 150,233 | 118,533 | 1,252,989 |
TOTAL | $4,427,000 | $7,458,219 | $7,920,995 | $3,005,843 | $1,321,770 |
Total Liabilities | $10,834,000 | $11,696,120 | $10,435,780 | $5,470,793 | $3,193,401 |
Shareholders' Equity | |||||
Shares Outstanding, K | 1,538,253 | 1,522,393 | 1,514,631 | 1,590,529 | 1,806,758 |
Common Shares | 2,000 | 1,519 | 753 | 802 | 900 |
Retained earnings | 6,106,000 | 3,704,744 | 1,776,760 | 1,183,730 | 1,995,272 |
Other shareholders' equity | 251,000 | 195,515 | 186,693 | 289,019 | 132,335 |
TOTAL | $11,745,000 | $9,543,722 | $6,867,349 | $6,121,837 | $6,505,158 |
Total Liabilities And Equity | $22,579,000 | $21,239,842 | $17,303,129 | $11,592,630 | $9,698,559 |